Valbiotis SA
EPA:ALVAL.PA
Overview | Financials
Company Name | Valbiotis SA |
Symbol | ALVAL.PA |
Currency | EUR |
Price | 1.332 |
Market Cap | 21,017,962 |
Dividend Yield | 0% |
52-week-range | 1.07 - 7.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sebastien Peltier HDR, Ph.D. |
Website | https://www.valbiotis.com |
An error occurred while fetching data.
About Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD